343 related articles for article (PubMed ID: 27009372)
1. Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials.
Nguyen E; White CM; Patel MR; Fields LE; Peacock WF; Crivera C; Coleman CI
Curr Med Res Opin; 2016 Jul; 32(7):1277-9. PubMed ID: 27009372
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Apixaban Versus Rivaroxaban for Patients With Atrial Fibrillation.
Ann Intern Med; 2020 Apr; 172(7):. PubMed ID: 32150747
[No Abstract] [Full Text] [Related]
3. Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study.
Fralick M; Colacci M; Schneeweiss S; Huybrechts KF; Lin KJ; Gagne JJ
Ann Intern Med; 2020 Apr; 172(7):463-473. PubMed ID: 32150751
[TBL] [Abstract][Full Text] [Related]
4. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
[TBL] [Abstract][Full Text] [Related]
5. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
7. Apixaban and rivaroxaban in patients with cerebral venous thrombosis.
Covut F; Kewan T; Perez O; Flores M; Haddad A; Daw H
Thromb Res; 2019 Jan; 173():77-78. PubMed ID: 30481600
[No Abstract] [Full Text] [Related]
8. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
9. Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
Alamneh EA; Chalmers L; Bereznicki LR
Am J Cardiovasc Drugs; 2016 Jun; 16(3):183-200. PubMed ID: 26862063
[TBL] [Abstract][Full Text] [Related]
10. Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.
Eek AK; Øie E; Granas AG
Eur J Clin Pharmacol; 2018 Mar; 74(3):323-330. PubMed ID: 29149366
[TBL] [Abstract][Full Text] [Related]
11. Initial apixaban dosing in patients with atrial fibrillation.
Buchholz A; Ueberham L; Gorczynska K; Dinov B; Hilbert S; Dagres N; Husser D; Hindricks G; Bollmann A
Clin Cardiol; 2018 May; 41(5):671-676. PubMed ID: 29542830
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation.
Jelonek O; Gorczyca I; Bączek M; Kośmider P; Wożakowska-Kapłon B
Kardiol Pol; 2018; 76(7):1073-1080. PubMed ID: 29441513
[TBL] [Abstract][Full Text] [Related]
13. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
Otsuka Y; Choules MP; Bonate PL; Komatsu K
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
Barra ME; Fanikos J; Connors JM; Sylvester KW; Piazza G; Goldhaber SZ
Am J Med; 2016 Nov; 129(11):1198-1204. PubMed ID: 27341955
[TBL] [Abstract][Full Text] [Related]
15. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulants: What is new and what is the standard?
Lesko LJ
Clin Pharmacol Ther; 2016 Aug; 100(2):126-8. PubMed ID: 27197625
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation.
Yoshimura A; Iriki Y; Ichiki H; Oketani N; Okui H; Maenosono R; Namino F; Miyata M; Ohishi M
J Cardiol; 2017 Jan; 69(1):228-235. PubMed ID: 27131792
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
Hernandez I; Zhang Y; Saba S
Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
[TBL] [Abstract][Full Text] [Related]
19. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
[TBL] [Abstract][Full Text] [Related]
20. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
